SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Lupin gains on acquiring Nanomi B.V.

04 Feb 2014 Evaluate

Lupin is currently trading at Rs. 923.50, up by 1.60 points or 0.17% from its previous closing of Rs. 921.90 on the BSE.

The scrip opened at Rs. 923.10 and has touched a high and low of Rs. 934.70 and Rs. 922.00 respectively. So far 22,000 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 951.00 on 06-Jan-2014 and a 52 week low of Rs. 569.00 on 01-Mar-2013.

Last one week high and low of the scrip stood at Rs. 934.70 and Rs. 855.00 respectively. The current market cap of the company is Rs. 41,467.00 crore.

The promoters holding in the company stood at 46.76% while Institutions and Non-Institutions held 43.22% and 10.02% respectively.

Pharmaceutical major Lupin has acquired Netherlands-based Nanomi B.V. With this acquisition, the company has made its foray into the technology intensive complex injectables space.

Nanomi has patented technology platforms to develop complex injectable products. Nanomi has a rich talent pool of scientists who would be backed by Lupin’s global R&D and manufacturing teams.

Lupin is an innovation led transnational pharmaceutical company producing and developing a wide range of branded and generic formulations and APIs globally. The company reported 18.97% rise in its net profit at Rs 533.38 crore for the quarter as compared to Rs 448.30 crore for the same quarter in the previous year.

Lupin Share Price

2245.65 -132.25 (-5.56%)
11-May-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1872.40
Dr. Reddys Lab 1279.70
Cipla 1304.70
Zydus Lifesciences 956.65
Lupin 2245.65
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×